In this study, we have demonstrated for the first time that a novel imidazopyridine carboxamide-based GSK3 inhibitor, CG0009, inhibits proliferation, induces apoptosis cell death, and activates the p53-Bax pathway in breast cancer cells, predominantly via cyclin D1 depletion. Here, TP53 is linked to breast carcinoma.